Cannabech, which is involved in the development of a botanical drug based on the extraction of the Cyathus striatus fungus and cannabinoids from the cannabis plant, reports that in an experiment conducted on a cell model, the fungus extract eliminated 100% of the pancreatic cancer cells relatively selectively and without damage to normal cells. 22
The fungus has been in research to test its anti-cancer efficacy in Prof. Fouad Fares’ laboratory at the University of Haifa for about 8 years and was selected as the preferred candidate for the development of a drug for pancreatic and colon cancer after showing better anti-cancer results than a variety of other fungi tested. Several months ago, Kenbotek received global and exclusive use rights for patents created in Prof. Fares’ research and began leading an accelerated process of developing a botanical drug as defined by the FDA.
The first milestone in the botanical drug development process was defined as the adaptation of fungal growth and extraction methods to the FDA protocol for botanical drug development which the company expects to be significantly cheaper and shorter than the standard drug development process. In addition, the anti-cancer activity of the new fungal extract and the cannabinoid composition developed by Cannabotek on pancreatic cancer were examined.
Kenbotek CEO, Elhanan Shaked “We have completed a significant milestone on the way to developing the botanical drug for pancreatic cancer. This is another step that brings us closer to the great vision we set for ourselves and investors about three years ago. I am confident we will continue to meet the deadlines and within 12 months A large pharmaceutical company, facing the FDA. “